EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Misrepresentation of semaglutide in social media

Lara Elisabeth Propfe, Roland Seifert

Naunyn-Schmiedeberg's Archives of Pharmacology · 2026-01 · 399 (1) · 815-832

DOI: 10.1007/s00210-025-04403-5 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Naunyn-Schmiedeberg's Archives of Pharmacology, online erschienen am 19.07.2025. Verfasst von Lara Elisabeth Propfe und 1 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Pharmacology, Hannover Medical School, Carl-Neuberg-Str. 1, D-30655, Hannover, Germany. Hauptthemen laut MEDLINE: Social Media, Glucagon-Like Peptides, Anti-Obesity Agents. Die Arbeit wurde bisher 38-mal zitiert (Crossref) und nennt 67 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Medizinische Hochschule Hannover (MHH).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

In recent years, semaglutide has repeatedly attracted attention in the press and on social media due to its effects in weight management. The social media hype led to off-label use and global supply shortages. Our goal was to identify differences in the presentation of semaglutide on individual social media platforms. Additionally, we aim to investigate the mentioning of various aspects such as adverse drug reactions, drug indications, supply shortages, and costs. Current social media trends regarding semaglutide were also included in the analysis. We collected semaglutide-related posts from the social media platforms Instagram, TikTok, X, Facebook, and YouTube. The posts were then analysed and compared with the adverse drug reactions presented in the STEP trials. Semaglutide was presented by social media users almost exclusively for weight reduction. Misrepresentation of the pharmacological properties of semaglutide with respect to mechanism of action, indication, adverse effects, and drug interactions was very common on social media. The important aspect of treatment costs and supply shortages was barely covered, if at all. Most content creators on Instagram and TikTok were female semaglutide users without medical knowledge. Strikingly, the very common gastrointestinal problems during semaglutide therapy were not even mentioned on Instagram. Some of the posts found under the hashtag “ozempic” advertised products that did not contain semaglutide. Violations of the Medicinal Products Act were also identified. Videos of weight loss results have a high probability of artificial intelligence (AI) modification, which can lead to user deception. Social media often provides misleading information, especially regarding drug indications and adverse drug reactions. YouTube has emerged as the most reputable platform for medical information, whereas Instagram provides the least medical knowledge. Misinformation and AI-modified videos can negatively impact the self-perception of young social media users, leading to unreflected medication use.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Social MediaGlucagon-Like PeptidesAnti-Obesity AgentsHumansOff-Label UseFemale

Stichwörter der Autor:innen

GLP-1 receptor agonistOzempicSemaglutideSocial mediaType 2 diabetes mellitusWegovyWeight loss

Substanzen

Glucagon-Like PeptidesAnti-Obesity Agents

Autor:innen und Institutionen

  • Institute of Pharmacology, Hannover Medical School, Carl-Neuberg-Str. 1, D-30655, Hannover, Germany.
  • Institute of Pharmacology, Hannover Medical School, Carl-Neuberg-Str. 1, D-30655, Hannover, Germany. seifert.roland@mh-hannover.de.

Förderung

  • Medizinische Hochschule Hannover (MHH)

Zitieren

APA

Propfe, L. E., & Seifert, R. (2026). Misrepresentation of semaglutide in social media. Naunyn-Schmiedeberg's Archives of Pharmacology, 399(1), 815-832. https://doi.org/10.1007/s00210-025-04403-5

Vancouver

Propfe LE, Seifert R. Misrepresentation of semaglutide in social media. Naunyn-Schmiedeberg's Archives of Pharmacology. 2026;399(1):815-832. doi:10.1007/s00210-025-04403-5

BibTeX
@article{Propfe2026,
  author = {Propfe, Lara Elisabeth and Seifert, Roland},
  title = {Misrepresentation of semaglutide in social media},
  journal = {Naunyn-Schmiedeberg's Archives of Pharmacology},
  year = {2026},
  volume = {399},
  number = {1},
  pages = {815--832},
  doi = {10.1007/s00210-025-04403-5}
}
Kostenlos starten →